GVM±R in Patients With Relapsed or Refractory Aggressive NHL.


Report Abuse


This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).

Study Overview

Start Date
January 17, 2024
Completion Date
June 30, 2027
Date Posted
February 6, 2024
Accepts Healthy Volunteers?


Full Address
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC
Tianjin, Tianjin 300020, China


Minimum Age (years)
Maximum Age (years)
Eligibility Criteria
Inclusion Criteria:

Age ≥18, ≤65 years.
Expected survival ≥ 3 months.
Subjects with aggressive NHL who have relapsed or proven refractory to at least one line of standard therapy or have achieved PR as the best response after a minimum of 4 cycles of therapy (patients with a Deauville score of 4 must have biopsy-proven residual disease). Relapse is defined as a disease response (PR/CR) to the last-line therapy with a duration of response exceeding 6 months. Refractory disease can be confirmed under any of the following conditions: 1) no partial or complete response to the last-line therapy; 2) the duration of complete or partial response to the last-line therapy is no longer than 6 months from the last dose of therapy; 3) Recurrence after hematopoietic stem cell transplantation.
Subjects must have at least one measurable lesion per lugano2014 criteria: for lymph node lesions, the long diameter should be > 1.5cm; For non-lymph node lesions, the long diameter should be > 1.0cm;
Eastern Cooperative Oncology Group (ECOG) : 0-2
Peripheral blood: Absolute neutrophil count (ANC) ≥1.5×109/L, Platelet count (PLT) ≥75×109/L, Hemoglobin(HB)≥ 80g/L.(Restriction may be relaxed in patients with bone marrow involvement, Absolute neutrophil count (ANC) ≥1.0×109/L, Platelet count (PLT) ≥50×109/L, Hemoglobin(HB)≥ 75g/L).
Liver and kidney function: Serum creatinine (Scr) ≤1.5X upper limit of normal (ULN).Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5X ULN, Total bilirubin (TBIL) ≤1.5X upper limit of normal (ULN).(If the lymphoma involves the liver, TBIL≤3 X ULN.AST and ALT≤5 X ULN). For Pts diagnosed with Gilbert's disease, TBIL was enrolled if it was ≤3 X ULN.-

Exclusion Criteria:

The subject had previously received any of the following anti-tumor treatments:

Subjects who have been treated with mitoxantrone or mitoxantrone liposomes;
Previously received doxorubicin or other anthracycline treatment, and the total cumulative dose of doxorubicin was more than 360 mg/m2 (For other anthracyclines, 1 mg doxorubicin equivalent to 2 mg epirubicin);
Subjects who received anti-tumor treatment (including chemotherapy, targeted therapy, glucocorticoid, traditional Chinese medicine with anti-tumor activity, etc.) or participated in other clinical trials and received trial drugs within 4 weeks or 5 half-lives((whichever comes first) before the first administration of the study drugs;
Subjects who received autologous hematopoietic stem cell transplantation or allogeneic hematopoietic stem cell transplantation within 100 days before the first administration of study drugs;
Subjects who received chimeric antigen receptor T-cell (CAR-T) therapy.
Hypersensitivity to any study drug or its components.
Uncontrolled systemic diseases (such as active infection, uncontrolled hypertension, diabetes, etc.)

Heart function and disease meet one of the following conditions:

Long QTc syndrome or QTc interval > 480 ms;
Complete left bundle branch block, grade II or III atrioventricular block;
Serious and uncontrolled arrhythmias requiring drug treatment;
New York Heart Association grade ≥ III;
Left Ventricular Ejection Fractions (LVEF)< 50%;
A history of myocardial infarction, unstable angina pectoris, severe unstable ventricular arrhythmia or any other arrhythmia requiring treatment, a history of clinically serious pericardial disease, or ECG evidence of acute ischemia or active conduction system abnormalities within 6 months before recruitment.
Active hepatitis B and C infection (defined as hepatitis B virus surface antigen positive and hepatitis B virus DNA higher than the Upper limit of normal(ULN); Hepatitis C virus antibody positive and hepatitis C virus RNA higher than the Upper limit of normal).
Human immunodeficiency virus (HIV) infection (defined as HIV antibody positive).
Patients with other malignant tumors, except for effectively controlled non-melanoma skin basal cell carcinoma, breast/cervical carcinoma in situ or other tumors without treatment during the past 5 years.
Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures.
≥ Grade 3 neuritis.
Active central nervous system (CNS) lymphoma;
Unsuitable subjects for this study determined by the investigator. -

Study Contact Info

Study Contact Name
Wei Liu
Study Contact Email
Study Contact Phone

Contact Listings Owner Form

GVM±R in Patients With Relapsed or Refractory Aggressive NHL. 0 reviews

Write Your Review

There are no reviews yet.

Write Your Review

Your email address will not be published. Required fields are marked *

Other Details

FDA Regulated Drug?
FDA Regulated Device?
Detailed Description
This is a single-arm, open label, multi-center clinical study to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in combination with gemcitabine, vinorelbine and/or anti-CD20 monoclonal antibody(GVM ± R) in patients with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL).Mitoxantrone hydrochloride liposome will be given on day 1 at dose of 18 mg/m2 and be combined with gemcitabine, vinorelbine and/or rituximab (Pts with CD20-positive lymphomas are evaluated by the investigator on whether to combine rituximab or choose another CD20 monoclonal antibody).Each cycle consists of 21 days. A maximum of 6 cycles of therapy are planned.
NCTid (if applicable)